<!DOCTYPE html><html lang="zh-cmn-Hans" class="font-n"><head><meta charSet="utf-8"/><meta name="viewport" content="width=device-width, initial-scale=1, maximum-scale=1, minimum-scale=1, user-scalable=no, viewport-fit=cover"/><meta name="format-detection" content="telephone=no"/><meta http-equiv="X-UA-Compatible" content="IE=Edge,chrome=1"/><link rel="dns-prefetch" href="//mat1.gtimg.com"/><link rel="dns-prefetch" href="//pacaio.match.qq.com"/><link rel="dns-prefetch" href="//inews.gtimg.com"/><link rel="dns-prefetch" href="//h5.ssp.qq.com"/><link rel="dns-prefetch" href="//news.ssp.qq.com"/><link rel="dns-prefetch" href="//pgdt.gtimg.cn"/><link rel="preload" href="//pacaio.match.qq.com/stat/only?callback=isNaN" as="script"/><meta name="theme-color" content="#ffffff"/><link rel="apple-touch-icon" href="//mat1.gtimg.com/www/mobi/2017/image/apple-touch-icon.png"/><link rel="icon" sizes="192x192" href="//mat1.gtimg.com/www/mobi/2017/image/logo/v0/192.png"/><link rel="shortcut icon" href="https://www.qq.com/favicon.ico" type="image/x-icon"/><link rel="manifest" href="/manifest.json"/><meta name="google-site-verification" content="oDqtSx_LCMXqEq2k089rP1KLjjblhg8pOzFVRktQi8M"/><style>/*! minireset.css v0.0.3 | MIT License | github.com/jgthms/minireset.css */html,body,p,ol,ul,li,dl,dt,dd,blockquote,figure,fieldset,legend,textarea,pre,iframe,hr,h1,h2,h3,h4,h5,h6{margin:0;padding:0}h1,h2,h3,h4,h5,h6{font-size:100%;font-weight:normal}ul{list-style:none}button,input,select,textarea{margin:0}html{box-sizing:border-box}*,*:before,*:after{box-sizing:inherit}embed,iframe,object,audio,video{height:auto;max-width:100%}iframe{border:0}table{border-collapse:collapse;border-spacing:0}td,th{padding:0;text-align:left}</style><style>html, body {font-family: -apple-system, BlinkMacSystemFont, &quot;Segoe UI&quot;, &quot;Roboto&quot;, &quot;Oxygen&quot;, &quot;Ubuntu&quot;, &quot;Cantarell&quot;, &quot;Fira Sans&quot;, &quot;Droid Sans&quot;, &quot;Helvetica Neue&quot;, &quot;Microsoft Yahei&quot;, sans-serif;}</style><style>html {font-size: 100px;} body {font-size: 16px;}</style><script>
            (function(base, min, max, scaling){
              var cacheWidth = 0;
              var timer;
              var docEl = document.documentElement;
              var resizeEvt = 'onorientationchange' in window ? 'orientationchange' : 'resize';
              var recalc = function () {
                var clientWidth = docEl.clientWidth;
                if (!clientWidth) return;
                clientWidth = Math.min(clientWidth, max);
                clientWidth = Math.max(clientWidth, min);
                if(cacheWidth !== clientWidth) {
                  clearInterval(timer);
                  cacheWidth = clientWidth;
                  docEl.style.fontSize = scaling * (clientWidth / base) + 'px';
                }
              }
              recalc();
              setTimeout(recalc, 300)
              if (!document.addEventListener) return;
              window.addEventListener(resizeEvt, function() {
                timer = setInterval(recalc, 10);
              });
            })(375, 300, 414, 100);
          </script><script src="//pacaio.match.qq.com/stat/only?callback=isNaN" async="" defer=""></script><title>大输液龙头联盟坐拥140亿市场“求变”！科伦13个高端仿制来袭、石四药进军吸入剂</title><link rel="amphtml" href="https://xw.qq.com/amphtml/20200709A0L1RH00"/><link rel="apple-touch-icon" href="http://inews.gtimg.com/newsapp_ls/0/12060397152_150120/0"/><link rel="apple-touch-icon" sizes="120x120" href="http://inews.gtimg.com/newsapp_ls/0/12060397152_150120/0"/><meta name="keywords" content="科伦药业,药企,中国公立医疗机构,科伦,石四药集团,腾讯新闻,腾讯网"/><meta name="description" content="精彩内容7月以来，大输液龙头药企不断传来好消息：科伦药业拿下了辉瑞全球超$20亿大品种枸橼酸托法替布片的国内仿制；石四药的头孢地尼胶囊也进入“在审批”状态，即将于近期获批……最近几年“限输限抗”的实……"/><script type="application/ld+json">{"@context":"http://schema.org","@type":"NewsArticle","headline":"大输液龙头联盟坐拥140亿市场“求变”！科伦13个高端仿制来袭、石四药进军吸入剂","datePublished":"2020-07-09T16:39:35+08:00","dateModified":"2020-07-09T16:39:35+08:00","image":["http://inews.gtimg.com/newsapp_ls/0/12060397152_640330/0"]}</script><meta name="next-head-count" content="29"/><link rel="preload" href="https://mat1.gtimg.com/qqcdn/xw/_next/static/bekAlVtaYh21RwYRjAoGs/pages/article/%5Bid%5D.js" as="script"/><link rel="preload" href="https://mat1.gtimg.com/qqcdn/xw/_next/static/bekAlVtaYh21RwYRjAoGs/pages/_app.js" as="script"/><link rel="preload" href="https://mat1.gtimg.com/qqcdn/xw/_next/static/runtime/webpack-18ae683764305191afa9.js" as="script"/><link rel="preload" href="https://mat1.gtimg.com/qqcdn/xw/_next/static/chunks/commons.0fb0bbc5a22735ff67b2.js" as="script"/><link rel="preload" href="https://mat1.gtimg.com/qqcdn/xw/_next/static/runtime/main-51bf4e043424b8340bb5.js" as="script"/><style id="__jsx-3967532495">.root.jsx-3967532495{height:100%;width:0px;position:absolute;z-index:2;}.inner.jsx-3967532495{position:relative;z-index:-1;visibility:hidden;display:none;}.inner.show.jsx-3967532495{z-index:100;display:block;visibility:visible;}.inner.jsx-3967532495 .tvp-wrap.jsx-3967532495{position:absolute;top:0;right:0;bottom:0;left:0;background:#CCC;border-radius:3px;-webkit-transform:scale(1);-ms-transform:scale(1);transform:scale(1);}.inner.jsx-3967532495 .mute.jsx-3967532495{position:absolute;right:0.12rem;bottom:0.52rem;width:0.26rem;height:0.26rem;}</style><style id="__jsx-68091983">.root-pic.jsx-68091983{position:fixed;top:0px;left:0px;width:100%;height:100%;}</style><style id="__jsx-3067894286">a.jsx-3067894286{color:inherit;font-size:inherit;-webkit-text-decoration:none;text-decoration:none;outline:none;}</style><style id="__jsx-1355058077">.main.jsx-1355058077{display:block;position:relative;padding:0.12rem 0.12rem 0.04rem 0.09rem;z-index:5;background:#537BFF;}.average.jsx-1355058077{padding:0.1rem 0.12rem 0.1rem 0.09rem;}.followom.jsx-1355058077{position:absolute;right:0.5rem;top:50%;-webkit-transform:translate(0,-50%);-ms-transform:translate(0,-50%);transform:translate(0,-50%);}header.omlist_article.isOmPinned.jsx-1355058077 .followom.jsx-1355058077{right:0.9rem;}.main.skin-blue.jsx-1355058077{background:#537bff;}.main.skin-black.jsx-1355058077{background:#222;}.main.jsx-1355058077 .gohome.jsx-1355058077{display:inline-block;vertical-align:top;-webkit-text-decoration:none;text-decoration:none;padding-right:0.1rem;position:relative;color:#fff;font-size:0.18rem;height:0.24rem;line-height:0.24rem;padding-left:0.27rem;background-image:url(//mat1.gtimg.com/www/mobi/2017/image/ui-icon_log.svg);background-size:0.24rem 0.24rem;background-position:0 center;background-repeat:no-repeat;}.main.jsx-1355058077 .gohome.nologo.jsx-1355058077{background-image:url(//mat1.gtimg.com/pingjs/ext2020/xw-article-icons/newui/back-home-arrow.svg);}.main.jsx-1355058077 .gohome.jsx-1355058077::after{content:'';position:absolute;width:0.01rem;height:0.18rem;right:0;top:50%;margin-top:-0.09rem;-webkit-transform:scaleX(0.5);-ms-transform:scaleX(0.5);transform:scaleX(0.5);-webkit-transform-origin:left bottom;-ms-transform-origin:left bottom;transform-origin:left bottom;background:rgba(224,242,255,1);}.main.jsx-1355058077 .title.jsx-1355058077{display:inline-block;vertical-align:top;width:1.3rem;white-space:nowrap;overflow:hidden;text-overflow:ellipsis;font-size:0.18rem;color:#fff;text-align:left;margin-left:0.09rem;line-height:0.24rem;position:relative;}.main.jsx-1355058077 .login.jsx-1355058077{position:relative;float:right;top:-0.01rem;right:unset;margin-right:0.09rem;}.main.jsx-1355058077 .sort.jsx-1355058077{position:relative;width:0.24rem;height:0.24rem;line-height:0.24rem;float:right;}.main.jsx-1355058077 .sort.jsx-1355058077 img.jsx-1355058077{position:absolute;top:0;left:0;width:100%;height:100%;}</style><style id="__jsx-1225297045">.subrow-wrap.sticky.jsx-1225297045{position:fixed;top:0;left:50%;-webkit-transform:translate(-50%,0);-ms-transform:translate(-50%,0);transform:translate(-50%,0);z-index:8;width:100%;max-width:768px;background:#537BFF;}.sticky-placeholder.jsx-1225297045{display:none;}</style><style id="__jsx-717484942">.title.jsx-717484942{font-size:0.21rem;padding:0.16rem 0 0.15rem;font-family:"PingFangSC-Medium";color:#222;-webkit-letter-spacing:0;-moz-letter-spacing:0;-ms-letter-spacing:0;letter-spacing:0;line-height:0.32rem;font-weight:400;}@media (max-width:380px){.title.jsx-717484942{font-size:0.22rem;line-height:0.34rem;}}.meta.jsx-717484942{font-size:0.12rem;color:#828C9B;line-height:0.24rem;height:0.24rem;margin-bottom:0.24rem;overflow:hidden;}.author.jsx-717484942{float:left;margin-right:0.1rem;color:#909AA4;-webkit-text-decoration:none;text-decoration:none;-webkit-tap-highlight-color:transparent;}.author.omauthor.jsx-717484942{color:#4C7EFF;font-family:"PingFangSC-Medium";}.author.omauthor.jsx-717484942 i.jsx-717484942{float:left;margin-right:0.06rem;width:0.22rem;height:0.22rem;background:url(//mat1.gtimg.com/pingjs/ext2020/xw-article-icons/newui/om-author-icon.svg) center no-repeat;background-size:contain;}.pubtime.jsx-717484942{height:0.14rem;float:left;font-family:Helvetica;}.follow_top.jsx-717484942{position:absolute;right:0.18rem;bottom:0;}.comment.jsx-717484942{width:0.87rem;height:0.24rem;background:rgba(238,84,74,0.12);border-radius:0.12rem;font-size:0.12rem;color:rgba(238,84,74,1);line-height:0.24rem;text-align:center;}.comment.jsx-717484942::before{content:'';display:inline-block;height:0.24rem;width:0.16rem;margin-right:0.02rem;background:url(https://mat1.gtimg.com/rain/bailing20/1c0a2bcb3dde.icon_hotcomment.svg) no-repeat center 0.035rem;vertical-align:top;}</style><style id="__jsx-237180751">a{-webkit-text-decoration:none;text-decoration:none;outline:none;}.text a{color:#537bff;border-bottom:1px dashed #537bff;}.text h2{font-weight:normal;font-family:'PingfangSC-Medium';color:#222;font-size:0.2rem;line-height:0.3rem;margin:0 0 0.18rem;}.text li{list-style:none;}.text li .time{color:rgb(136,136,136);}.text li .time::before{content:"";display:inline-block;width:0.07rem;height:0.07rem;margin-right:0.1rem;position:relative;top:-0.02rem;background:#537bff;border-radius:50%;}</style><style id="__jsx-2078701242">.video-wrapper.jsx-428399900{position:absolute;width:100%;padding-top:56.25%;}.summary.jsx-428399900{position:relative;word-wrap:break-word;color:#828C9B;margin-bottom:0.4rem;text-align:justify;word-break:break-all;}.summary.jsx-428399900:after,.summary.jsx-428399900:before{background:url(//mat1.gtimg.com/pingjs/ext2020/xw-article-icons/summary-line.svg) left top no-repeat;content:'';display:block;height:0.05rem;width:100%;background-size:contain;}.summary.jsx-428399900:before{margin-bottom:0.12rem;}.summary.jsx-428399900:after{background-position:bottom left;position:absolute;right:0;bottom:-0.24rem;-webkit-transform:rotate(180deg);-ms-transform:rotate(180deg);transform:rotate(180deg);}.text.jsx-428399900{overflow-wrap:break-word;margin-bottom:20px;text-align:justify;word-break:break-all;color:rgb(34,34,34);}.summary.jsx-428399900,.text.jsx-428399900{line-height:0.28rem;font-size:0.17rem;}@media (max-width:380px){.summary.jsx-428399900,.text.jsx-428399900{font-size:0.18rem;line-height:0.3rem;}}.font-s .summary.jsx-428399900{font-size:0.15rem;line-height:0.26rem;}.font-s .text.jsx-428399900{font-size:0.15rem;line-height:0.26rem;}@media (max-width:380px){.font-s .summary.jsx-428399900{font-size:0.16rem;line-height:0.28rem;}.font-s .text.jsx-428399900{font-size:0.16rem;line-height:0.28rem;}}.font-l .summary.jsx-428399900{font-size:0.19rem;line-height:0.30rem;}.font-l .text.jsx-428399900{font-size:0.19rem;line-height:0.30rem;}@media (max-width:380px){.font-l .summary.jsx-428399900{font-size:0.20rem;line-height:0.32rem;}.font-l .text.jsx-428399900{font-size:0.20rem;line-height:0.32rem;}}.font-xl .summary.jsx-428399900{font-size:0.21rem;line-height:0.32rem;}.font-xl .text.jsx-428399900{font-size:0.21rem;line-height:0.32rem;}@media (max-width:380px){.font-xl .summary.jsx-428399900{font-size:0.22rem;line-height:0.34rem;}.font-xl .text.jsx-428399900{font-size:0.22rem;line-height:0.34rem;}}.pic.jsx-428399900{margin-bottom:20px;}.pic.jsx-428399900 img.jsx-428399900{max-width:100%;}.responsive-image.jsx-428399900{display:block;font-size:0px;position:relative;margin:0px auto;overflow:hidden;}.image-wrap.jsx-428399900{position:absolute;top:0px;right:0px;bottom:0px;left:0px;background-color:rgb(234,234,234);background-image:url(//mat1.gtimg.com/www/mobi/2017/image/image-placeholder-logo.svg);background-size:45px 45px;background-position:center center;background-repeat:no-repeat;}.imggif.jsx-428399900{position:absolute;color:rgb(255,255,255);font-size:12px;bottom:0px;right:0px;height:22px;line-height:22px;pointer-events:none;background:rgba(67,138,254,0.8);padding:0px 6px;}.video.jsx-428399900{margin-bottom:20px;}.video-inner.jsx-428399900{position:relative;padding-top:56.25%;background:#000 center no-repeat;background-size:contain;}.video-player.jsx-428399900{position:absolute;top:0;width:100%;height:100%;}.play-icon.jsx-428399900{position:absolute;z-index:0;width:68px;height:68px;left:50%;top:50%;font-size:0px;-webkit-transform:translate(-50%,-50%);-ms-transform:translate(-50%,-50%);transform:translate(-50%,-50%);background-image:url(//mat1.gtimg.com/www/mobi/2017/image/play-circle_v2.svg);background-size:contain;border-radius:50%;}.live_container.jsx-428399900{position:absolute;top:0;left:0;width:100%;height:100%;}.desc.jsx-428399900{display:block;font-size:0.16rem;color:#828C9B;line-height:0.22rem;text-align:left;text-indent:0px;margin:0.09rem 0px 0.24rem;}.zdlist.jsx-428399900{color:rgb(102,102,102);line-height:1.5625rem;margin-bottom:20px;overflow-wrap:break-word;text-align:justify;word-break:break-all;background:rgb(246,246,246);padding:20px 18px 0px;overflow:hidden;counter-reset:item;}.zdlist.jsx-428399900 li.jsx-428399900{margin-bottom:0.17rem;padding-left:0.36rem;position:relative;list-style-type:none;counter-increment:item;}.zdlist.jsx-428399900 li.jsx-428399900::before{content:counter(item);color:#537bff;display:inline-block;font-style:normal;width:0.2rem;height:0.2rem;text-align:center;font-size:0.14rem;line-height:0.16rem;font-weight:700;position:absolute;left:0px;top:0.04rem;border-width:2px;border-style:solid;border-color:#537bff;border-image:initial;}.grouppic.jsx-428399900{display:block;-webkit-text-decoration:none;text-decoration:none;}.grouppic-inner.jsx-428399900{position:relative;font-size:0;}.grouppic-inner.jsx-428399900 img.jsx-428399900{width:100%;}.grouppic.jsx-428399900 .totalnum.jsx-428399900{position:absolute;bottom:0.12rem;right:0.06rem;color:rgb(255,255,255);font-size:0.1rem;background-color:rgba(0,0,0,0.4);height:0.18rem;line-height:0.18rem;border-radius:0.09rem;padding:0px 0.12rem;}.truthContainer.jsx-428399900{color:rgb(102,102,102);font-size:1rem;margin-bottom:20px;padding:20px 18px;background:rgb(246,246,246);}.truthHeader.jsx-428399900{width:55px;height:19px;margin-bottom:20px;background:url(//mat1.gtimg.com/www/mobi/2017/image/truthheader.png) 0% 0% / contain no-repeat;}.time_axis.jsx-428399900{color:rgb(51,51,51);line-height:25px;font-size:1rem;margin-bottom:20px;padding:18px 20px;background:rgb(246,246,246);}.timeline-time.jsx-428399900{color:rgb(136,136,136);font-size:0.17rem;}.timeline-time.jsx-428399900:before{content:"";display:inline-block;width:7px;height:7px;margin-right:10px;position:relative;left:-2px;top:-2px;background:rgb(67,138,254);border-radius:50%;}.timeline-event.jsx-428399900{padding-left:12px;border-left:2px solid rgb(229,229,229);}.gif-loading.jsx-428399900{width:40px;height:40px;position:absolute;top:50%;left:50%;margin-left:-20px;margin-top:-20px;color:rgb(255,255,255);text-align:center;font-size:14px;line-height:40px;background:rgba(0,0,0,0.6);border-radius:50%;}.circle-loading.jsx-428399900{position:absolute;top:0px;left:0px;bottom:0px;right:0px;background:url(//mat1.gtimg.com/www/mobi/2017/image/loading-gif-shape.png) center center / 34px no-repeat;-webkit-animation:gifloading-jsx-428399900 1s linear 0s infinite normal none running;animation:gifloading-jsx-428399900 1s linear 0s infinite normal none running;}.mobvideo.jsx-428399900{margin-bottom:20px;}.mobvideo.jsx-428399900 .a-inner.jsx-428399900{position:relative;display:block;width:100%;min-height:150px;overflow:hidden;background:#000 no-repeat center;background-size:contain;padding-top:56.25%;}.playBtn.jsx-428399900{width:45px;height:45px;position:absolute;left:10px;bottom:16px;background:url(//mat1.gtimg.com/www/mobi/2017/image/play-circle_v2.svg) 0% 0% / 100% 100%;}.bottomDesc.jsx-428399900{position:absolute;bottom:16px;right:10px;color:rgb(255,255,255);font-size:12px;line-height:20px;background-color:rgba(0,0,0,0.6);padding:0px 5px;border-radius:3px;}.bottomTitle.jsx-428399900{text-align:center;position:relative;display:block;color:rgb(71,128,229);background-color:rgb(255,255,255);font-size:14px;overflow:hidden;border-width:1px 1px 1px;border-style:none solid solid;border-color:rgb(228,228,228) rgb(228,228,228) rgb(228,228,228);border-image:initial;border-top:none;padding:10px 0px;-webkit-text-decoration:none;text-decoration:none;}</style><style id="__jsx-1893092673">.hairline-top.jsx-1893092673,.hairline-bottom.jsx-1893092673,.hairline-both.jsx-1893092673{position:relative;overflow:hidden;}.hairline-top.jsx-1893092673::before,.hairline-bottom.jsx-1893092673::after,.hairline-both.jsx-1893092673::before,.hairline-both.jsx-1893092673::after,.landad.jsx-1893092673::before{content:'';display:block;position:absolute;left:0.15rem;right:0.15rem;background:#e9e9e9;height:0.01rem;-webkit-transform:scaleY(0.5);-ms-transform:scaleY(0.5);transform:scaleY(0.5);-webkit-transform-origin:bottom left;-ms-transform-origin:bottom left;transform-origin:bottom left;}.hairline-top.jsx-1893092673::before,.hairline-both.jsx-1893092673::before{top:0;}.hairline-bottom.jsx-1893092673::after,.hairline-both.jsx-1893092673::after{bottom:0;}.landad.jsx-1893092673{position:relative;}.landad.jsx-1893092673::before{top:0;left:0.15rem;right:0.15rem;}.landad-inner.jsx-1893092673{position:static;background:#fff;}.landad-fixed.jsx-1893092673{position:fixed;z-index:6;bottom:0.73rem;-webkit-transform:translate(-50%,100%);-ms-transform:translate(-50%,100%);transform:translate(-50%,100%);left:50%;width:100%;max-width:768px;box-shadow:0px -2px 6px rgba(5,27,86,0.24);margin-bottom:constant(safe-area-inset-bottom);margin-bottom:env(safe-area-inset-bottom);}.bannerimg.jsx-1893092673{width:100%;padding:0 0.15rem;margin:0.12rem 0;}.bannerimg.jsx-1893092673 img.jsx-1893092673{display:block;width:100%;border-radius:0.04rem;}</style><style id="__jsx-671811996">.gap.jsx-671811996{display:block;position:relative;min-height:7px;background-color:#F7F8FA;font-size:0;}</style><style id="__jsx-3712844012">.nav.jsx-3712844012{background-color:#F0F8FF;font-size:0;}.nav.jsx-3712844012 ol.jsx-3712844012{padding:7px 2.4%;}.nav.jsx-3712844012 ol.jsx-3712844012 li.jsx-3712844012{display:inline-block;width:14.2857%;line-height:32px;vertical-align:top;}.nav.jsx-3712844012 ol.jsx-3712844012 li.jsx-3712844012 a.jsx-3712844012{display:block;position:relative;text-align:center;font-size:16px;font-weight:400;color:#636871;-webkit-text-decoration:none;text-decoration:none;white-space:nowrap;}.nav.jsx-3712844012 ol.jsx-3712844012 li.jsx-3712844012 a.placeholder.jsx-3712844012{color:#bbb;}.nav.jsx-3712844012 ol.jsx-3712844012 li.jsx-3712844012 a.reddot.jsx-3712844012::after{content:'';display:block;position:absolute;top:4px;right:0px;background:#ed5151;width:6px;height:6px;border-radius:50%;}@media screen and (max-width:350px){.nav.jsx-3712844012 ol.jsx-3712844012 li.jsx-3712844012 a.text-length-4.jsx-3712844012{font-size:12px;}}.nav.skin-2019ny.jsx-3712844012{background-color:#FFF4F0;}</style><style id="__jsx-287773377">.footer.jsx-287773377{background:#F7F8FA;color:#A8ABB0;font-size:12px;padding:23px 0;text-align:center;position:relative;}.footer.jsx-287773377 .links.jsx-287773377{margin-bottom:15px;}.footer.jsx-287773377 .links.jsx-287773377 a.jsx-287773377{color:#7D8189;-webkit-text-decoration:none;text-decoration:none;display:inline-block;margin-right:10px;}.footer.jsx-287773377 .links.jsx-287773377 a.jsx-287773377+a.jsx-287773377{padding-left:10px;border-left:1px solid #E0E0E0;}.copyright.jsx-287773377{font-size:12px;}</style><style id="__jsx-2472896812">.top-red.jsx-2472896812{display:block;position:relative;height:58px;}.audio-wrap.jsx-2472896812{margin:0 0.18rem 0.12rem;height:0.4rem;}audio.jsx-2472896812{width:100%;height:100%;}.follow_bottom.jsx-2472896812{position:absolute;top:16px;right:0;}.isom.jsx-2472896812{margin:15px 0 20px;font-size:14px;color:#909aa4;line-height:20px;position:relative;}.primary.jsx-2472896812{padding:0 0.18rem;position:relative;}#article_body.jsx-2472896812{margin:0 0.18rem;overflow:hidden;position:relative;max-height:1010px;}#article_body.packed.jsx-2472896812{max-height:1000px;}#article_body.unpack.jsx-2472896812{max-height:none;}.mask.jsx-2472896812{background:url(//mat1.gtimg.com/www/mobi/2017/image/linearlayer.png) repeat-x;background:linear-gradient( -180deg, rgba(255,255,255,0) 0%, rgba(255,255,255,0.6) 49%, #ffffff 85% );position:absolute;width:100%;bottom:0;left:0;height:70px;z-index:5;border:none;}.collapseWrapper.jsx-2472896812{margin-bottom:0.24rem;position:relative;top:4px;background:#fff;z-index:5;}.comment_download.jsx-2472896812{background:#ededed;display:block;-webkit-text-decoration:none;text-decoration:none;border-radius:6px;font-size:14px;height:40px;position:relative;text-align:center;line-height:40px;color:#56bb56;margin:0 12px 20px;}.comment_download.jsx-2472896812 img.jsx-2472896812{display:inline-block;vertical-align:middle;width:19px;margin-top:-2px;}.landad.jsx-2472896812{position:relative;z-index:4;}.icon-content-more.jsx-2472896812{display:block;height:0.32rem;width:0.32rem;margin:0px auto;}.content-more.jsx-2472896812{height:0.46rem;background:rgba(69,116,255,1);border-radius:0.06rem;margin:0.16rem 0.18rem;font-size:0.16rem;font-family:PingFangSC-Regular,PingFang SC;color:rgba(255,255,255,1);line-height:0.46rem;text-align:center;}.channel-entry.jsx-2472896812 a.jsx-2472896812{display:block;margin-bottom:0.16rem;text-align:center;font-size:0.15rem;font-weight:500;color:#537bfe;line-height:0.16rem;-webkit-text-decoration:none;text-decoration:none;}.channel-entry.jsx-2472896812 a.jsx-2472896812::after{content:'';background:url(//mat1.gtimg.com/pingjs/ext2020/xw-article-icons/icon_article_more.svg) center no-repeat;background-size:contain;display:inline-block;width:0.16rem;height:0.16rem;vertical-align:text-bottom;}</style><style id="__jsx-3538576898">@-webkit-keyframes showTips-jsx-3538576898{0%{-webkit-transform:translateY(-100%);-ms-transform:translateY(-100%);transform:translateY(-100%);}10%{-webkit-transform:translateY(0);-ms-transform:translateY(0);transform:translateY(0);}90%{-webkit-transform:translateY(0);-ms-transform:translateY(0);transform:translateY(0);}100%{-webkit-transform:translateY(-100%);-ms-transform:translateY(-100%);transform:translateY(-100%);}}@keyframes showTips-jsx-3538576898{0%{-webkit-transform:translateY(-100%);-ms-transform:translateY(-100%);transform:translateY(-100%);}10%{-webkit-transform:translateY(0);-ms-transform:translateY(0);transform:translateY(0);}90%{-webkit-transform:translateY(0);-ms-transform:translateY(0);transform:translateY(0);}100%{-webkit-transform:translateY(-100%);-ms-transform:translateY(-100%);transform:translateY(-100%);}}.tips.jsx-3538576898{display:none;position:fixed;top:0;left:0;z-index:8;overflow:hidden;width:100%;min-height:0.3rem;line-height:0.2rem;padding:0.05rem;box-sizing:border-box;text-align:center;word-break:break-all;color:#fff;font-size:0.14rem;background-color:rgba(68,138,255,.9);-webkit-transform:translateY(-100%);-ms-transform:translateY(-100%);transform:translateY(-100%);will-change:transform;}.tips.show.jsx-3538576898{display:block;-webkit-animation-name:showTips-jsx-3538576898;animation-name:showTips-jsx-3538576898;-webkit-animation-duration:2800ms;animation-duration:2800ms;-webkit-animation-iteration-count:1;animation-iteration-count:1;}</style></head><body><div id="__next"><div style="position:relative" class="__xw_app"><div class="jsx-3967532495 root"><div class="jsx-3967532495 inner "><div id="mod_player" class="jsx-3967532495 tvp-wrap"></div></div></div><div id="__xw_float_view_root"></div><div id="__xw_next_view_root"><div style="max-width:768px;margin:0px auto" class="jsx-2472896812"><div style="visibility:hidden" class="jsx-2472896812"><div class="headroom-wrapper"><div style="position:relative;top:0;left:0;right:0;z-index:11;-webkit-transform:translate3D(0, 0, 0);-ms-transform:translate3D(0, 0, 0);transform:translate3D(0, 0, 0);max-width:768px;margin:0 auto" class="headroom headroom--unfixed"><div class="jsx-1225297045 ch-nav"><div class="jsx-1355058077 main average"><a data-boss="home&amp;modular=head" href="/" target="_self" class="jsx-1355058077 gohome ">首页</a><div class="jsx-1355058077 title"><a style="-webkit-tap-highlight-color:transparent" class="jsx-3067894286 ">新闻</a></div><a href="/m/s/sort" data-boss="qzdh&amp;modular=head" class="jsx-1355058077 more sort"><img src="data:image/svg+xml;base64,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" alt="更多频道" class="jsx-1355058077"/></a></div></div></div></div></div><div class="jsx-2472896812 main-wrapper "><div class="jsx-2472896812 primary"><h1 class="jsx-717484942 title">大输液龙头联盟坐拥140亿市场“求变”！科伦13个高端仿制来袭、石四药进军吸入剂</h1><div class="jsx-717484942 meta"><a href="/m/author?id=6451326" data-boss="author&amp;modular=author" class="jsx-717484942 author omauthor"><i class="jsx-717484942"></i><span class="jsx-717484942">杏林大数据</span></a><div id="subtime" class="jsx-717484942 pubtime">07-09 16:39</div></div></div><div id="article_body" class="jsx-2472896812 "><div class="jsx-428399900"><div class="jsx-428399900 text"><STRONG>精彩内容</STRONG></div><div class="jsx-428399900 text">7月以来，大输液龙头药企不断传来好消息：科伦药业拿下了辉瑞全球超$20亿大品种枸橼酸托法替布片的国内仿制；石四药的头孢地尼胶囊也进入“在审批”状态，即将于近期获批……最近几年“限输限抗”的实施，令大输液头部药企加速转型，科伦与石四药联盟建造起了“大输液王国”，市场地位稳固，作为独立的公司，他们各自都有新的非输液产品获批，市场竞争力越发夯实。</div><div class="jsx-428399900 text"><STRONG>科伦+石四药，坐拥140亿大输液市场</STRONG></div><div class="jsx-428399900 text">表1：最近几年科伦药业持股石四药集团的具体情况</div><div class="jsx-428399900 text">来源：公司年报</div><div class="jsx-428399900 text">科伦药业早在2012年就想进入利君国际(石四药集团前身)，但被港交所以“一致行动人，未来可能触发全面收购”为理由而否决。2014年科伦药业以3.98亿元曲折接盘1.45亿股，占比4.96%，进入石四药集团，并且后续逐年增加股份直至20%。最近三年，科伦药业对于石四药集团的持股比例（直接+间接）保持在20%左右，可见双方对于联手构建大输液王国的同盟关系相当认可。</div><div class="jsx-428399900 text">科伦药业与石四药集团的联盟，不是单纯的龙头企业抱团，而是优势互补、可持续发展的双赢局面：从产品结构来看，科伦药业的塑瓶市场占有率高，而石四药则以标准软袋为主，对石四药软包产品线的对标学习有助于科伦不断提升产品质量、降低单位成本。在销售区域方面，科伦药业集中于中南地区，而石四药的核心市场处于北方，科伦药业也能借助石四药销售渠道拓宽新产品在北方的销售规模。</div><div class="jsx-428399900 text">表2：近几年输液业务的营收情况（单位：亿元）</div><div class="jsx-428399900 text">来源：公司年报，输液指50ml以上大容量注射剂</div><div class="jsx-428399900 text">强强联合之下，最近几年两家大输液巨头的业绩也在一路攀升：科伦药业最近三年输液业务营业收入增长率分别为26.12%、30.37%、5.86%，2019年顺利突破百亿；石四药最近三年的输液业务营收增速为35%、32.7%、4.9%。2017年起，两大巨头联盟合计输液业务营收达100亿，2019年接近140亿元。</div><div class="jsx-428399900 text">近几年，在环保加强、输液管控、限抗等政策持续影响下，大输液行业集中度不断提升，随着行业洗牌，相关企业已经开始了转型。从输液业务占公司总收入的比例可以看出，科伦药业的输液业务占比已经降至59%，而石四药目前占比仍超过80%。</div><div class="jsx-428399900 text"><STRONG>科伦新品上市进入井喷期，13个高端仿制来袭</STRONG></div><div class="jsx-428399900 text">表3：科伦药业2017年至今获批上市的部分非输液产品情况</div><div data-boss="pic&amp;modular=content" class="jsx-428399900 pic"><div style="max-width:641px" class="jsx-428399900 responsive-image"><div style="padding-top:76.91%" class="jsx-428399900 sizer"></div><div data-boss-expo="pic&amp;modular=content" data-boss-once="true" class="jsx-428399900 image-wrap"></div></div></div><div class="jsx-428399900 text">来源：米内网MED中国药品审评数据库2.0</div><div class="jsx-428399900 text">科伦药业以大输液起家，在2012年成立科伦研究院后逐渐建立起仿制药与创新药研发管线，经过多年孵化，近几年公司多个新品陆续获批，呈现井喷的态势。获批上市的非输液产品涉及多个领域，注射剂仍是该公司的主力方向，片剂、散剂、滴眼液也有新突破。</div><div class="jsx-428399900 text">2017年至今获批的非输液新品中，有多个超10亿产品备受市场关注。米内网数据显示，2019年在中国城市公立医院、县级公立医院、城市社区中心及乡镇卫生院（简称中国公立医疗机构）终端，注射用帕瑞昔布钠的销售额接近20亿元（领军企业为辉瑞），盐酸右美托咪定注射液销售额接近36亿元（领军企业为江苏恒瑞医药），盐酸氨溴索注射液销售额接近36亿元（领军企业为勃林格殷格翰），吉非替尼片销售额超过21亿元（领军企业为阿斯利康），注射用头孢硫脒销售额超过25亿元（领军企业为白云山制药总厂），注射用美洛西林钠舒巴坦钠(4:1)销售额接近30亿元（领军企业瑞阳制药）。</div><div class="jsx-428399900 text">表4：科伦药业2019年至今在审的部分非输液产品上市申请情况</div><div data-boss="pic&amp;modular=content" class="jsx-428399900 pic"><div style="max-width:641px" class="jsx-428399900 responsive-image"><div style="padding-top:58.660000000000004%" class="jsx-428399900 sizer"></div><div data-boss-expo="pic&amp;modular=content" data-boss-once="true" class="jsx-428399900 image-wrap"></div></div></div><div class="jsx-428399900 text">来源：米内网MED中国药品审评数据库2.0</div><div class="jsx-428399900 text">据米内网MED中国药品审评数据库2.0，2019年至今科伦药业有13个非输液产品的上市申请在审评审批中，有望在2020年迎来好消息，这些在审的产品中，不乏市场重磅产品：盐酸莫西沙星片在中国公立医疗机构终端销售额近10亿元（领军企业是拜耳），氟比洛芬酯注射液销售额超过18亿元（领军企业为北京泰德制药），塞来昔布胶囊销售额超过10亿元（领军企业为G.D.Searle），奥氮平片销售额超过40亿元（领军企业为江苏豪森药业集团）。</div><div class="jsx-428399900 text">此外，富马酸丙酚替诺福韦片、盐酸莫西沙星滴眼液、甲磺酸仑伐替尼胶囊、钆特醇注射液、环孢素眼用乳剂5个产品有望夺下国内首仿。富马酸丙酚替诺福韦片竞争激烈，目前有包括正大天晴在内的15家药企在审评审批中；盐酸莫西沙星滴眼液有兴齐眼药等10家企业的仿制上市申请在审；甲磺酸仑伐替尼胶囊有齐鲁在内的7家药企仿制上市申请在审；钆特醇注射液、环孢素眼用乳剂目前仅有科伦申报仿制上市并在审，拿下首仿是大概率事件。</div><div class="jsx-428399900 text">年报数据显示，科伦药业2017至2019年的研发投入分别为8.46亿元、11.14亿元、13.51亿元，每年增长均超过20%。从近几年科伦的获批、申报情况来看，公司的新品研发逐渐向高端、重磅产品延伸，此外，两个1类新药未来可期，注射用SKB264已于2020年1月获批临床，KL-A289注射液临床申请在审。可见，科伦药业除了牢牢把握大输液龙头地位，在转型之路上正往制剂龙头的目标发展。</div><div class="jsx-428399900 text"><STRONG>石四药进军吸入剂，与健康元“正面刚”</STRONG></div><div class="jsx-428399900 text">与科伦药业“家大业大”相比，石四药的规模稍逊一筹，但在大输液领域的专注度同样出色，2017-2018年公司的营收及净利润增长率（按人民币计算）均保持在30%以上，2019年在大环境影响之下，营收（按人民币计算）增长15.3%，净利润（按人民币计算）增长29.6%。</div><div class="jsx-428399900 text">表5：石四药2017年至今获批上市的部分非输液产品情况</div><div data-boss="pic&amp;modular=content" class="jsx-428399900 pic"><div style="max-width:641px" class="jsx-428399900 responsive-image"><div style="padding-top:36.04%" class="jsx-428399900 sizer"></div><div data-boss-expo="pic&amp;modular=content" data-boss-once="true" class="jsx-428399900 image-wrap"></div></div></div><div class="jsx-428399900 text">来源：米内网MED中国药品审评数据库2.0</div><div class="jsx-428399900 text">2017年，石四药集团先后获批建立院士工作站、诺奖工作站，积极申报了国家企业技术中心，药物研发取得重大进展。2018年三个注射剂6类仿制上市获批，盐酸氨溴索注射液为超10亿品种；2020年两个注射剂4类仿制上市获批并视同过评，目前多索茶碱注射液、盐酸罗哌卡因注射液仅石四药1家过评。</div><div class="jsx-428399900 text">表6：石四药2019年至今在审的部分非输液产品上市申请情况</div><div class="jsx-428399900 text">来源：米内网MED中国药品审评数据库2.0</div><div class="jsx-428399900 text">米内网数据显示</div><div class="jsx-428399900 text">，2019年至今石四药有6个非输液产品的上市申请在审，这些即将获批上市产品中不乏片剂、吸入剂、散剂、胶囊剂的身影，这些在审产品均为3、4类仿制，从中亦可看出石四药正向高端仿制路线靠拢。</div><div class="jsx-428399900 text">盐酸右美托咪定注射液获得批文的企业有10家，仅有扬子江1家过评，石四药按3类仿制申报，若获批则视同过评，目前该产品申报3类仿制并在审的企业共有7家；硫酸特布他林雾化吸入用溶液2019年在中国公立医疗机构终端销售额超过13亿元（领军企业为阿斯利康），2020年4月四川美大康华康药业的6类仿制获批为国内首仿，目前除了石四药，还有健康元等3家药企的4类仿制在审，首家过评之争激烈；头孢地尼胶囊销售额超过15亿元，目前仅有领军企业江苏豪森药业集团的产品过评，石四药及成都倍特药业的4类仿制上市申请均已进入“在审批”状态。</div><div class="jsx-428399900 text">2020年1月，石四药的1类新药NP-01片申报临床，目前在审评审批中，该产品用于治疗肿瘤。据悉，研究表明，NP-01在胃癌、肝癌、肺癌、前列腺癌等多种肿瘤动物模型中表现出优异的抗肿瘤活性，全球尚无同靶点药物获批上市。</div><div class="jsx-428399900 text"><STRONG>结语</STRONG></div><div class="jsx-428399900 text">近年来，国家鼓励创新，创新型药企受到业界以及资本的热捧；国家集采等政策实施以来，仿制药市场洗牌，药企纷纷转型高端仿制。大输液行业在优胜劣汰之下，市场集中度逐渐提高，龙头联盟立于不败之地，但“限输限抗”影响有增无减，行业增速走下坡已是不争的事实，科伦凭借“家底丰厚”早年间已开始布局转型，目前非输液新品上市进入井喷期，多个1类新药获批临床，大有向创新型药企进发的意味；石四药不断紧握输液市场领导地位，研发上开拓新领域，目前吸入剂是行业大热，进口品牌当道，国产品牌潜力可期。</div><div class="jsx-428399900 text">来源：公司年报、米内网数据库</div><div class="jsx-428399900 text">审评数据统计截至2020年7月9日，如有错漏，敬请指正。</div></div><div data-boss-expo="end&amp;modular=content" data-boss-once="true" class="jsx-2472896812"></div><div class="jsx-2472896812 isom">免责声明：本文来自腾讯新闻客户端自媒体，不代表腾讯新闻、腾讯网的观点和立场。</div></div><div style="height:0.01rem" class="jsx-1893092673 hairline-top"></div><div class="jsx-671811996 gap"></div><div data-boss-expo="&amp;modular=map" class="jsx-2472896812"><div style="background-color:#fff" class="jsx-3712844012 nav skin-default"><ol class="jsx-3712844012"><li class="jsx-3712844012"><a href="/m/s/sort" data-boss="map&amp;map=more&amp;modular=bottom" class="jsx-3712844012">更多</a></li></ol></div></div><div style="top:0" class="jsx-287773377 footer hasnav"><div class="jsx-287773377 links"><a href="https://support.qq.com/products/14842" data-boss="feedback&amp;modular=bottom" class="jsx-287773377 feedback">反馈</a><a href="http://report.12377.cn:13225/toreportinputNormal_anis.do" data-boss="rcenter&amp;modular=bottom" class="jsx-287773377">举报中心</a><a href="https://privacy.qq.com/yszc-m.htm" data-boss="privacy&amp;modular=bottom" class="jsx-287773377">隐私政策</a><a href="https://new.qq.com/omn/20200709/20200709A0L1RH00.html?pc" data-boss="pc&amp;modular=bottom" class="jsx-287773377 pcs">电脑版</a></div><div class="jsx-287773377 copyright">Copyright © 1998 - <!-- -->2020<!-- --> Tencent. All Rights Reserved</div></div></div><div data-boss="message" class="jsx-2472896812"></div></div></div><div class="jsx-3538576898 tips "><span class="jsx-3538576898"></span></div></div><script src="//mat1.gtimg.com/www/https/pingjs20161020.js"></script></div><script id="__NEXT_DATA__" type="application/json">{"dataManager":"[]","props":{"pageProps":{"pageConfig":{"key":"article","disableAutoPush":true,"includeManifest":true,"registerServiceWorker":true,"includeGSV":true,"remLayout":{"enabled":true,"range":[300,414]},"bossConfig":{"options":{"pagetype":"article","channel":"","page":"ptdc","pre_id":"20200709A0L1RH00","category_ori":""}},"pgvConfig":{"options":{"pgv_site":"cmsid","useUnofficialJS":true}}},"data":{"data":{"channel":["ywexpand"],"content":{"abstract":"精彩内容7月以来，大输液龙头药企不断传来好消息：科伦药业拿下了辉瑞全球超$20亿大品种枸橼酸托法替布片的国内仿制；石四药的头孢地尼胶囊也进入“在审批”状态，即将于近期获批……最近几年“限输限抗”的实……","abstract_count":300,"abstract_pad":"精彩内容　7月以来，大输液龙头药企不断传来好消息：科伦药业拿下了辉瑞全球超$20亿大品种枸橼酸托法替布片的国内仿制；石四药的头孢地尼胶囊也进入“在审批”状态，即将于近期获批……最近几年“限输限抗”的实施，令大输液头部药企加速转型，科伦与石四药联盟建造起了“大输液王国”，市场地位稳固，作为独立的公司，他们各自都有新的非输液产品获批，市场竞争力越发夯实。　科伦+石四药，坐拥140亿大输液市场　表1：最近几年科伦药业持股石四药集团的具体情况　来源：公司年报　科伦药业早在2012年就想进入利君国际(石四药集团前身)，但被港交所以“一致行动人，未来可能触发全面收购”为理由而否决。2014年科伦药业以3.98亿元曲折接盘1.45亿","alt_time":"2020-07-09 16:41:06","apply_exclusive_flag":0,"apply_firstpub_flag":0,"apply_olympic_flag":0,"apply_original_flag":1,"apply_push_flag":0,"art_ad_switch":"1","article_id":"20200709A0L1RH","atype":"0","category_id":null,"chlid":"6451326","chlname":"杏林大数据","choose_comment":0,"cid":"5531466252","cnt_attr":{"IMG_0":{"count":1,"desc":"","face":"","fullPic":"1","has180":"1","img":{"imgurl0":{"height":649,"imgurl":"http://inews.gtimg.com/newsapp_match/0/12060383789/0","length":129,"width":843},"imgurl1000":{"height":649,"imgurl":"http://inews.gtimg.com/newsapp_bt/0/12060383789/1000","width":843},"imgurl640":{"height":480,"imgurl":"http://inews.gtimg.com/newsapp_bt/0/12060383789/640","width":623},"imgurl641":{"height":493,"imgurl":"http://inews.gtimg.com/newsapp_bt/0/12060383789/641","width":641}},"islong":0,"isqrcode":0,"itype":2},"IMG_1":{"count":1,"desc":"","face":"","fullPic":"1","has180":"1","img":{"imgurl0":{"height":496,"imgurl":"http://inews.gtimg.com/newsapp_match/0/12060383790/0","length":72,"width":845},"imgurl1000":{"height":496,"imgurl":"http://inews.gtimg.com/newsapp_bt/0/12060383790/1000","width":845},"imgurl640":{"height":376,"imgurl":"http://inews.gtimg.com/newsapp_bt/0/12060383790/640","width":640},"imgurl641":{"height":376,"imgurl":"http://inews.gtimg.com/newsapp_bt/0/12060383790/641","width":641}},"islong":0,"isqrcode":0,"itype":2},"IMG_2":{"count":1,"desc":"","face":"","fullPic":"1","has180":"1","img":{"imgurl0":{"height":304,"imgurl":"http://inews.gtimg.com/newsapp_match/0/12060383791/0","length":58,"width":844},"imgurl1000":{"height":304,"imgurl":"http://inews.gtimg.com/newsapp_bt/0/12060383791/1000","width":844},"imgurl640":{"height":231,"imgurl":"http://inews.gtimg.com/newsapp_bt/0/12060383791/640","width":640},"imgurl641":{"height":231,"imgurl":"http://inews.gtimg.com/newsapp_bt/0/12060383791/641","width":641}},"islong":0,"isqrcode":0,"itype":2}},"cnt_html":"\u003cP\u003e\u003cSTRONG\u003e精彩内容\u003c/STRONG\u003e\u003c/P\u003e\u003cP\u003e7月以来，大输液龙头药企不断传来好消息：科伦药业拿下了辉瑞全球超$20亿大品种枸橼酸托法替布片的国内仿制；石四药的头孢地尼胶囊也进入“在审批”状态，即将于近期获批……最近几年“限输限抗”的实施，令大输液头部药企加速转型，科伦与石四药联盟建造起了“大输液王国”，市场地位稳固，作为独立的公司，他们各自都有新的非输液产品获批，市场竞争力越发夯实。\u003c/P\u003e\u003cP\u003e\u003cSTRONG\u003e科伦+石四药，坐拥140亿大输液市场\u003c/STRONG\u003e\u003c/P\u003e\u003cP\u003e表1：最近几年科伦药业持股石四药集团的具体情况\u003c/P\u003e\u003cP\u003e来源：公司年报\u003c/P\u003e\u003cP\u003e科伦药业早在2012年就想进入利君国际(石四药集团前身)，但被港交所以“一致行动人，未来可能触发全面收购”为理由而否决。2014年科伦药业以3.98亿元曲折接盘1.45亿股，占比4.96%，进入石四药集团，并且后续逐年增加股份直至20%。最近三年，科伦药业对于石四药集团的持股比例（直接+间接）保持在20%左右，可见双方对于联手构建大输液王国的同盟关系相当认可。\u003c/P\u003e\u003cP\u003e科伦药业与石四药集团的联盟，不是单纯的龙头企业抱团，而是优势互补、可持续发展的双赢局面：从产品结构来看，科伦药业的塑瓶市场占有率高，而石四药则以标准软袋为主，对石四药软包产品线的对标学习有助于科伦不断提升产品质量、降低单位成本。在销售区域方面，科伦药业集中于中南地区，而石四药的核心市场处于北方，科伦药业也能借助石四药销售渠道拓宽新产品在北方的销售规模。\u003c/P\u003e\u003cP\u003e表2：近几年输液业务的营收情况（单位：亿元）\u003c/P\u003e\u003cP\u003e来源：公司年报，输液指50ml以上大容量注射剂\u003c/P\u003e\u003cP\u003e强强联合之下，最近几年两家大输液巨头的业绩也在一路攀升：科伦药业最近三年输液业务营业收入增长率分别为26.12%、30.37%、5.86%，2019年顺利突破百亿；石四药最近三年的输液业务营收增速为35%、32.7%、4.9%。2017年起，两大巨头联盟合计输液业务营收达100亿，2019年接近140亿元。\u003c/P\u003e\u003cP\u003e近几年，在环保加强、输液管控、限抗等政策持续影响下，大输液行业集中度不断提升，随着行业洗牌，相关企业已经开始了转型。从输液业务占公司总收入的比例可以看出，科伦药业的输液业务占比已经降至59%，而石四药目前占比仍超过80%。\u003c/P\u003e\u003cP\u003e\u003cSTRONG\u003e科伦新品上市进入井喷期，13个高端仿制来袭\u003c/STRONG\u003e\u003c/P\u003e\u003cP\u003e表3：科伦药业2017年至今获批上市的部分非输液产品情况\u003c/P\u003e\u003cP\u003e\u003c!--IMG_0--\u003e\u003c/P\u003e\u003cP\u003e来源：米内网MED中国药品审评数据库2.0\u003c/P\u003e\u003cP\u003e科伦药业以大输液起家，在2012年成立科伦研究院后逐渐建立起仿制药与创新药研发管线，经过多年孵化，近几年公司多个新品陆续获批，呈现井喷的态势。获批上市的非输液产品涉及多个领域，注射剂仍是该公司的主力方向，片剂、散剂、滴眼液也有新突破。\u003c/P\u003e\u003cP\u003e2017年至今获批的非输液新品中，有多个超10亿产品备受市场关注。米内网数据显示，2019年在中国城市公立医院、县级公立医院、城市社区中心及乡镇卫生院（简称中国公立医疗机构）终端，注射用帕瑞昔布钠的销售额接近20亿元（领军企业为辉瑞），盐酸右美托咪定注射液销售额接近36亿元（领军企业为江苏恒瑞医药），盐酸氨溴索注射液销售额接近36亿元（领军企业为勃林格殷格翰），吉非替尼片销售额超过21亿元（领军企业为阿斯利康），注射用头孢硫脒销售额超过25亿元（领军企业为白云山制药总厂），注射用美洛西林钠舒巴坦钠(4:1)销售额接近30亿元（领军企业瑞阳制药）。\u003c/P\u003e\u003cP\u003e表4：科伦药业2019年至今在审的部分非输液产品上市申请情况\u003c/P\u003e\u003cP\u003e\u003c!--IMG_1--\u003e\u003c/P\u003e\u003cP\u003e来源：米内网MED中国药品审评数据库2.0\u003c/P\u003e\u003cP\u003e据米内网MED中国药品审评数据库2.0，2019年至今科伦药业有13个非输液产品的上市申请在审评审批中，有望在2020年迎来好消息，这些在审的产品中，不乏市场重磅产品：盐酸莫西沙星片在中国公立医疗机构终端销售额近10亿元（领军企业是拜耳），氟比洛芬酯注射液销售额超过18亿元（领军企业为北京泰德制药），塞来昔布胶囊销售额超过10亿元（领军企业为G.D.Searle），奥氮平片销售额超过40亿元（领军企业为江苏豪森药业集团）。\u003c/P\u003e\u003cP\u003e此外，富马酸丙酚替诺福韦片、盐酸莫西沙星滴眼液、甲磺酸仑伐替尼胶囊、钆特醇注射液、环孢素眼用乳剂5个产品有望夺下国内首仿。富马酸丙酚替诺福韦片竞争激烈，目前有包括正大天晴在内的15家药企在审评审批中；盐酸莫西沙星滴眼液有兴齐眼药等10家企业的仿制上市申请在审；甲磺酸仑伐替尼胶囊有齐鲁在内的7家药企仿制上市申请在审；钆特醇注射液、环孢素眼用乳剂目前仅有科伦申报仿制上市并在审，拿下首仿是大概率事件。\u003c/P\u003e\u003cP\u003e年报数据显示，科伦药业2017至2019年的研发投入分别为8.46亿元、11.14亿元、13.51亿元，每年增长均超过20%。从近几年科伦的获批、申报情况来看，公司的新品研发逐渐向高端、重磅产品延伸，此外，两个1类新药未来可期，注射用SKB264已于2020年1月获批临床，KL-A289注射液临床申请在审。可见，科伦药业除了牢牢把握大输液龙头地位，在转型之路上正往制剂龙头的目标发展。\u003c/P\u003e\u003cP\u003e\u003cSTRONG\u003e石四药进军吸入剂，与健康元“正面刚”\u003c/STRONG\u003e\u003c/P\u003e\u003cP\u003e与科伦药业“家大业大”相比，石四药的规模稍逊一筹，但在大输液领域的专注度同样出色，2017-2018年公司的营收及净利润增长率（按人民币计算）均保持在30%以上，2019年在大环境影响之下，营收（按人民币计算）增长15.3%，净利润（按人民币计算）增长29.6%。\u003c/P\u003e\u003cP\u003e表5：石四药2017年至今获批上市的部分非输液产品情况\u003c/P\u003e\u003cP\u003e\u003c!--IMG_2--\u003e\u003c/P\u003e\u003cP\u003e来源：米内网MED中国药品审评数据库2.0\u003c/P\u003e\u003cP\u003e2017年，石四药集团先后获批建立院士工作站、诺奖工作站，积极申报了国家企业技术中心，药物研发取得重大进展。2018年三个注射剂6类仿制上市获批，盐酸氨溴索注射液为超10亿品种；2020年两个注射剂4类仿制上市获批并视同过评，目前多索茶碱注射液、盐酸罗哌卡因注射液仅石四药1家过评。\u003c/P\u003e\u003cP\u003e表6：石四药2019年至今在审的部分非输液产品上市申请情况\u003c/P\u003e\u003cP\u003e来源：米内网MED中国药品审评数据库2.0\u003c/P\u003e\u003cP\u003e米内网数据显示\u003c/P\u003e\u003cP\u003e，2019年至今石四药有6个非输液产品的上市申请在审，这些即将获批上市产品中不乏片剂、吸入剂、散剂、胶囊剂的身影，这些在审产品均为3、4类仿制，从中亦可看出石四药正向高端仿制路线靠拢。\u003c/P\u003e\u003cP\u003e盐酸右美托咪定注射液获得批文的企业有10家，仅有扬子江1家过评，石四药按3类仿制申报，若获批则视同过评，目前该产品申报3类仿制并在审的企业共有7家；硫酸特布他林雾化吸入用溶液2019年在中国公立医疗机构终端销售额超过13亿元（领军企业为阿斯利康），2020年4月四川美大康华康药业的6类仿制获批为国内首仿，目前除了石四药，还有健康元等3家药企的4类仿制在审，首家过评之争激烈；头孢地尼胶囊销售额超过15亿元，目前仅有领军企业江苏豪森药业集团的产品过评，石四药及成都倍特药业的4类仿制上市申请均已进入“在审批”状态。\u003c/P\u003e\u003cP\u003e2020年1月，石四药的1类新药NP-01片申报临床，目前在审评审批中，该产品用于治疗肿瘤。据悉，研究表明，NP-01在胃癌、肝癌、肺癌、前列腺癌等多种肿瘤动物模型中表现出优异的抗肿瘤活性，全球尚无同靶点药物获批上市。\u003c/P\u003e\u003cP\u003e\u003cSTRONG\u003e结语\u003c/STRONG\u003e\u003c/P\u003e\u003cP\u003e近年来，国家鼓励创新，创新型药企受到业界以及资本的热捧；国家集采等政策实施以来，仿制药市场洗牌，药企纷纷转型高端仿制。大输液行业在优胜劣汰之下，市场集中度逐渐提高，龙头联盟立于不败之地，但“限输限抗”影响有增无减，行业增速走下坡已是不争的事实，科伦凭借“家底丰厚”早年间已开始布局转型，目前非输液新品上市进入井喷期，多个1类新药获批临床，大有向创新型药企进发的意味；石四药不断紧握输液市场领导地位，研发上开拓新领域，目前吸入剂是行业大热，进口品牌当道，国产品牌潜力可期。\u003c/P\u003e\u003cP\u003e来源：公司年报、米内网数据库\u003c/P\u003e\u003cP\u003e审评数据统计截至2020年7月9日，如有错漏，敬请指正。\u003c/P\u003e","content":[{"desc":"表6：石四药2019年至今在审的部分非输液产品上市申请情况","type":"cnt_article"},{"desc":"结语","type":"cnt_article"},{"desc":"精彩内容","type":"cnt_article"},{"desc":"科伦药业以大输液起家，在2012年成立科伦研究院后逐渐建立起仿制药与创新药研发管线，经过多年孵化，近几年公司多个新品陆续获批，呈现井喷的态势。获批上市的非输液产品涉及多个领域，注射剂仍是该公司的主力方向，片剂、散剂、滴眼液也有新突破。","type":"cnt_article"},{"desc":"此外，富马酸丙酚替诺福韦片、盐酸莫西沙星滴眼液、甲磺酸仑伐替尼胶囊、钆特醇注射液、环孢素眼用乳剂5个产品有望夺下国内首仿。富马酸丙酚替诺福韦片竞争激烈，目前有包括正大天晴在内的15家药企在审评审批中；盐酸莫西沙星滴眼液有兴齐眼药等10家企业的仿制上市申请在审；甲磺酸仑伐替尼胶囊有齐鲁在内的7家药企仿制上市申请在审；钆特醇注射液、环孢素眼用乳剂目前仅有科伦申报仿制上市并在审，拿下首仿是大概率事件。","type":"cnt_article"},{"desc":"与科伦药业“家大业大”相比，石四药的规模稍逊一筹，但在大输液领域的专注度同样出色，2017-2018年公司的营收及净利润增长率（按人民币计算）均保持在30%以上，2019年在大环境影响之下，营收（按人民币计算）增长15.3%，净利润（按人民币计算）增长29.6%。","type":"cnt_article"},{"count":1,"desc":null,"face":"","has180":"1","img":{"imgurl0":{"height":649,"imgurl":"http://inews.gtimg.com/newsapp_match/0/12060383789/0","length":129,"width":843},"imgurl1000":{"height":649,"imgurl":"http://inews.gtimg.com/newsapp_bt/0/12060383789/1000","width":843},"imgurl640":{"height":480,"imgurl":"http://inews.gtimg.com/newsapp_bt/0/12060383789/640","width":623},"imgurl641":{"height":493,"imgurl":"http://inews.gtimg.com/newsapp_bt/0/12060383789/641","width":641}},"img_url":"http://inews.gtimg.com/newsapp_match/0/12060383789/0","img_url_height":649,"img_url_width":843,"img_url_wifi":"http://inews.gtimg.com/newsapp_match/0/12060383789/0","islong":0,"isqrcode":0,"itype":2,"type":"img_url"},{"desc":"来源：米内网MED中国药品审评数据库2.0","type":"cnt_article"},{"desc":"石四药进军吸入剂，与健康元“正面刚”","type":"cnt_article"},{"desc":"米内网数据显示","type":"cnt_article"},{"desc":"，2019年至今石四药有6个非输液产品的上市申请在审，这些即将获批上市产品中不乏片剂、吸入剂、散剂、胶囊剂的身影，这些在审产品均为3、4类仿制，从中亦可看出石四药正向高端仿制路线靠拢。","type":"cnt_article"},{"desc":"表2：近几年输液业务的营收情况（单位：亿元）","type":"cnt_article"},{"desc":"强强联合之下，最近几年两家大输液巨头的业绩也在一路攀升：科伦药业最近三年输液业务营业收入增长率分别为26.12%、30.37%、5.86%，2019年顺利突破百亿；石四药最近三年的输液业务营收增速为35%、32.7%、4.9%。2017年起，两大巨头联盟合计输液业务营收达100亿，2019年接近140亿元。","type":"cnt_article"},{"desc":"2017年至今获批的非输液新品中，有多个超10亿产品备受市场关注。米内网数据显示，2019年在中国城市公立医院、县级公立医院、城市社区中心及乡镇卫生院（简称中国公立医疗机构）终端，注射用帕瑞昔布钠的销售额接近20亿元（领军企业为辉瑞），盐酸右美托咪定注射液销售额接近36亿元（领军企业为江苏恒瑞医药），盐酸氨溴索注射液销售额接近36亿元（领军企业为勃林格殷格翰），吉非替尼片销售额超过21亿元（领军企业为阿斯利康），注射用头孢硫脒销售额超过25亿元（领军企业为白云山制药总厂），注射用美洛西林钠舒巴坦钠(4:1)销售额接近30亿元（领军企业瑞阳制药）。","type":"cnt_article"},{"count":1,"desc":null,"face":"","has180":"1","img":{"imgurl0":{"height":304,"imgurl":"http://inews.gtimg.com/newsapp_match/0/12060383791/0","length":58,"width":844},"imgurl1000":{"height":304,"imgurl":"http://inews.gtimg.com/newsapp_bt/0/12060383791/1000","width":844},"imgurl640":{"height":231,"imgurl":"http://inews.gtimg.com/newsapp_bt/0/12060383791/640","width":640},"imgurl641":{"height":231,"imgurl":"http://inews.gtimg.com/newsapp_bt/0/12060383791/641","width":641}},"img_url":"http://inews.gtimg.com/newsapp_match/0/12060383791/0","img_url_height":304,"img_url_width":844,"img_url_wifi":"http://inews.gtimg.com/newsapp_match/0/12060383791/0","islong":0,"isqrcode":0,"itype":2,"type":"img_url"},{"desc":"来源：米内网MED中国药品审评数据库2.0","type":"cnt_article"},{"desc":"来源：公司年报、米内网数据库","type":"cnt_article"},{"desc":"科伦+石四药，坐拥140亿大输液市场","type":"cnt_article"},{"desc":"来源：公司年报","type":"cnt_article"},{"desc":"科伦药业与石四药集团的联盟，不是单纯的龙头企业抱团，而是优势互补、可持续发展的双赢局面：从产品结构来看，科伦药业的塑瓶市场占有率高，而石四药则以标准软袋为主，对石四药软包产品线的对标学习有助于科伦不断提升产品质量、降低单位成本。在销售区域方面，科伦药业集中于中南地区，而石四药的核心市场处于北方，科伦药业也能借助石四药销售渠道拓宽新产品在北方的销售规模。","type":"cnt_article"},{"desc":"近几年，在环保加强、输液管控、限抗等政策持续影响下，大输液行业集中度不断提升，随着行业洗牌，相关企业已经开始了转型。从输液业务占公司总收入的比例可以看出，科伦药业的输液业务占比已经降至59%，而石四药目前占比仍超过80%。","type":"cnt_article"},{"desc":"来源：米内网MED中国药品审评数据库2.0","type":"cnt_article"},{"desc":"2020年1月，石四药的1类新药NP-01片申报临床，目前在审评审批中，该产品用于治疗肿瘤。据悉，研究表明，NP-01在胃癌、肝癌、肺癌、前列腺癌等多种肿瘤动物模型中表现出优异的抗肿瘤活性，全球尚无同靶点药物获批上市。","type":"cnt_article"},{"desc":"表4：科伦药业2019年至今在审的部分非输液产品上市申请情况","type":"cnt_article"},{"desc":"来源：米内网MED中国药品审评数据库2.0","type":"cnt_article"},{"desc":"近年来，国家鼓励创新，创新型药企受到业界以及资本的热捧；国家集采等政策实施以来，仿制药市场洗牌，药企纷纷转型高端仿制。大输液行业在优胜劣汰之下，市场集中度逐渐提高，龙头联盟立于不败之地，但“限输限抗”影响有增无减，行业增速走下坡已是不争的事实，科伦凭借“家底丰厚”早年间已开始布局转型，目前非输液新品上市进入井喷期，多个1类新药获批临床，大有向创新型药企进发的意味；石四药不断紧握输液市场领导地位，研发上开拓新领域，目前吸入剂是行业大热，进口品牌当道，国产品牌潜力可期。","type":"cnt_article"},{"count":1,"desc":null,"face":"","has180":"1","img":{"imgurl0":{"height":496,"imgurl":"http://inews.gtimg.com/newsapp_match/0/12060383790/0","length":72,"width":845},"imgurl1000":{"height":496,"imgurl":"http://inews.gtimg.com/newsapp_bt/0/12060383790/1000","width":845},"imgurl640":{"height":376,"imgurl":"http://inews.gtimg.com/newsapp_bt/0/12060383790/640","width":640},"imgurl641":{"height":376,"imgurl":"http://inews.gtimg.com/newsapp_bt/0/12060383790/641","width":641}},"img_url":"http://inews.gtimg.com/newsapp_match/0/12060383790/0","img_url_height":496,"img_url_width":845,"img_url_wifi":"http://inews.gtimg.com/newsapp_match/0/12060383790/0","islong":0,"isqrcode":0,"itype":2,"type":"img_url"},{"desc":"年报数据显示，科伦药业2017至2019年的研发投入分别为8.46亿元、11.14亿元、13.51亿元，每年增长均超过20%。从近几年科伦的获批、申报情况来看，公司的新品研发逐渐向高端、重磅产品延伸，此外，两个1类新药未来可期，注射用SKB264已于2020年1月获批临床，KL-A289注射液临床申请在审。可见，科伦药业除了牢牢把握大输液龙头地位，在转型之路上正往制剂龙头的目标发展。","type":"cnt_article"},{"desc":"表5：石四药2017年至今获批上市的部分非输液产品情况","type":"cnt_article"},{"desc":"2017年，石四药集团先后获批建立院士工作站、诺奖工作站，积极申报了国家企业技术中心，药物研发取得重大进展。2018年三个注射剂6类仿制上市获批，盐酸氨溴索注射液为超10亿品种；2020年两个注射剂4类仿制上市获批并视同过评，目前多索茶碱注射液、盐酸罗哌卡因注射液仅石四药1家过评。","type":"cnt_article"},{"desc":"审评数据统计截至2020年7月9日，如有错漏，敬请指正。","type":"cnt_article"},{"desc":"科伦药业早在2012年就想进入利君国际(石四药集团前身)，但被港交所以“一致行动人，未来可能触发全面收购”为理由而否决。2014年科伦药业以3.98亿元曲折接盘1.45亿股，占比4.96%，进入石四药集团，并且后续逐年增加股份直至20%。最近三年，科伦药业对于石四药集团的持股比例（直接+间接）保持在20%左右，可见双方对于联手构建大输液王国的同盟关系相当认可。","type":"cnt_article"},{"desc":"来源：公司年报，输液指50ml以上大容量注射剂","type":"cnt_article"},{"desc":"表3：科伦药业2017年至今获批上市的部分非输液产品情况","type":"cnt_article"},{"desc":"据米内网MED中国药品审评数据库2.0，2019年至今科伦药业有13个非输液产品的上市申请在审评审批中，有望在2020年迎来好消息，这些在审的产品中，不乏市场重磅产品：盐酸莫西沙星片在中国公立医疗机构终端销售额近10亿元（领军企业是拜耳），氟比洛芬酯注射液销售额超过18亿元（领军企业为北京泰德制药），塞来昔布胶囊销售额超过10亿元（领军企业为G.D.Searle），奥氮平片销售额超过40亿元（领军企业为江苏豪森药业集团）。","type":"cnt_article"},{"desc":"盐酸右美托咪定注射液获得批文的企业有10家，仅有扬子江1家过评，石四药按3类仿制申报，若获批则视同过评，目前该产品申报3类仿制并在审的企业共有7家；硫酸特布他林雾化吸入用溶液2019年在中国公立医疗机构终端销售额超过13亿元（领军企业为阿斯利康），2020年4月四川美大康华康药业的6类仿制获批为国内首仿，目前除了石四药，还有健康元等3家药企的4类仿制在审，首家过评之争激烈；头孢地尼胶囊销售额超过15亿元，目前仅有领军企业江苏豪森药业集团的产品过评，石四药及成都倍特药业的4类仿制上市申请均已进入“在审批”状态。","type":"cnt_article"},{"desc":"7月以来，大输液龙头药企不断传来好消息：科伦药业拿下了辉瑞全球超$20亿大品种枸橼酸托法替布片的国内仿制；石四药的头孢地尼胶囊也进入“在审批”状态，即将于近期获批……最近几年“限输限抗”的实施，令大输液头部药企加速转型，科伦与石四药联盟建造起了“大输液王国”，市场地位稳固，作为独立的公司，他们各自都有新的非输液产品获批，市场竞争力越发夯实。","type":"cnt_article"},{"desc":"表1：最近几年科伦药业持股石四药集团的具体情况","type":"cnt_article"},{"desc":"科伦新品上市进入井喷期，13个高端仿制来袭","type":"cnt_article"}],"copyright_status":"1","del_flag":"0","desc":"精彩内容7月以来，大输液龙头药企不断传来好消息：科伦药业拿下了辉瑞全球超$20亿大品种枸橼酸托法替布片的国内仿制；石四药的头孢地尼胶囊也进入“在审批”状态，即将于近期获批……最近几年“限输限抗”的实……","ext":{"action":{"FallSizePic":"1","Fimgurl10":"http://inews.gtimg.com/newsapp_ls/0/12060397152_960495/0","Fimgurl11":"http://inews.gtimg.com/newsapp_ls/0/12060397152_300240/0","Fimgurl18":"http://inews.gtimg.com/newsapp_ls/0/12060396584_640330/0","Fimgurl24":"http://inews.gtimg.com/newsapp_ls/0/12060397152_1164606/0","Fimgurl26":"http://inews.gtimg.com/newsapp_ls/0/12060397152_640470/0","Fimgurl28":"http://inews.gtimg.com/newsapp_ls/0/12060397152_1200490/0","Fimgurl29":"http://inews.gtimg.com/newsapp_ls/0/12060397152_580328/0","Fimgurl30":"http://inews.gtimg.com/newsapp_ls/0/12060397152_870492/0","Fimgurl31":"http://inews.gtimg.com/newsapp_ls/0/12060397152_196130/0","Fimgurl32":"http://inews.gtimg.com/newsapp_ls/0/12060397152_294195/0","Fimgurl4":"http://inews.gtimg.com/newsapp_ls/0/12060397152_450330/0","Fimgurl41":"http://inews.gtimg.com/newsapp_ls/0/12060397303_295195/0,http://inews.gtimg.com/newsapp_ls/0/12060397304_295195/0,http://inews.gtimg.com/newsapp_ls/0/12060397305_295195/0","Fimgurl5":"http://inews.gtimg.com/newsapp_ls/0/12060397152_640330/0","Fimgurl7":"http://inews.gtimg.com/newsapp_ls/0/12060397152_150120/0","FisUserPickEnabled":"1","OMGCategory":-2,"browser_tag":{"st_compose":{"0":{"id":"200005461","is_valid_tag":true,"name":"科伦药业_财经","score":1,"type":"st_compose"}},"tag":{"0":{"id":"1800362","is_valid_tag":true,"name":"科伦药业","score":1,"type":"tag"},"1":{"id":"108828413","is_valid_tag":false,"name":"输液","score":0.9521384,"type":"tag"},"2":{"id":"2434403","is_valid_tag":false,"name":"药企","score":0.5258747,"type":"tag"},"3":{"id":"208020922","is_valid_tag":false,"name":"中国公立医疗机构","score":0.52103966,"type":"tag"},"4":{"id":"1003007","is_valid_tag":false,"name":"市场","score":0.5,"type":"tag"},"5":{"id":"108885813","is_valid_tag":true,"name":"石四药集团","score":0.5,"type":"tag"},"6":{"id":"108825868","is_valid_tag":false,"name":"吸入剂","score":0.5,"type":"tag"},"7":{"id":"1008841","is_valid_tag":false,"name":"联盟","score":0.4523327,"type":"tag"},"8":{"id":"108921093","is_valid_tag":false,"name":"注射液","score":0.44374293,"type":"tag"},"9":{"id":"108934202","is_valid_tag":false,"name":"米内网","score":0.39709404,"type":"tag"}},"topic":{"0":{"id":"124","is_valid_tag":false,"name":"finance","score":0.999572,"type":"topic"},"1":{"id":"12416","is_valid_tag":false,"name":"finance_corpnews","score":0.506343,"type":"topic"}}},"category_cn_name":"财经","category_id":"61","contentMd5":"66985caf11083dbf9d0d86a7be385ff5","dealOMGCategoryTime":1594284665,"iNewsRecommendLevel":1,"isOpenAdvertisement":"1","isOpenCommentAd":"1","isOpenPicsAd":"1","isOpenTextAd":"1","isSensitive":0,"isTop":0,"isUpdate":"1","level":"3","lite_is_hot":"1","lsImgExpType":"1","news_app_recommend_status":4,"news_category_cn":"财经","news_category_id":"12","news_category_name":"finance","news_sub_category_cn":"医药产业","news_sub_category_id":"1206","news_sub_category_name":"finance_yiyaojiankang","openRelatedNewsAd":"1","refInDocs":{"zt":{}},"relatedSearchQuery":null,"sensitiveWords":"","toneScore":"2"},"tags":{"0":"科伦药业","1":"药企","2":"中国公立医疗机构","3":"科伦","4":"石四药集团"}},"fans_need":"0","from":"cms_pool","hasTooManyQR":false,"has_rumor_text":0,"htmlIntro":"","htmlRemarks":"","id":"20200709A0L1RH00","idx":"1","image_count":3,"imgLostTooMuch":false,"img_que_final_res":"12060383789,12060383790,12060383791","img_que_final_res2":"http://inews.gtimg.com/newsapp_bt/0/12060383789/640,http://inews.gtimg.com/newsapp_bt/0/12060383790/640,http://inews.gtimg.com/newsapp_bt/0/12060383791/640","imgurl":"http://inews.gtimg.com/newsapp_ls/0/12060397152_640330/0","imgurl_ext":{"1":"http://inews.gtimg.com/newsapp_ls/0/12060383988/0","150110":"http://inews.gtimg.com/newsapp_ls/0/12060383988_150110/0","150120":"http://inews.gtimg.com/newsapp_ls/0/12060383988_150120/0","196130":"http://inews.gtimg.com/newsapp_ls/0/12060383988_196130/0","196140":"http://inews.gtimg.com/newsapp_ls/0/12060383988_196140/0","240180":"http://inews.gtimg.com/newsapp_ls/0/12060383988_240180/0","294195":"http://inews.gtimg.com/newsapp_ls/0/12060383988_294195/0","300240":"http://inews.gtimg.com/newsapp_ls/0/12060383988_300240/0","324204":"http://inews.gtimg.com/newsapp_ls/0/12060383988_324204/0","354222":"http://inews.gtimg.com/newsapp_ls/0/12060383988_354222/0","354264":"http://inews.gtimg.com/newsapp_ls/0/12060383988_354264/0","354354":"http://inews.gtimg.com/newsapp_ls/0/12060383988_354354/0","396246":"http://inews.gtimg.com/newsapp_ls/0/12060383988_396246/0","450360":"http://inews.gtimg.com/newsapp_ls/0/12060383988_450360/0","580300":"http://inews.gtimg.com/newsapp_ls/0/12060383988_580300/0"},"imgurl_small":"http://inews.gtimg.com/newsapp_ls/0/12060397152_150120/0","intro_name":"","isExclusive":"0","isFirstPubed":"0","isGreat":"0","isOriginal":"1","is_cleaned":1,"is_commercial":0,"ismodifyimg":0,"kb_ext":{"categoryId1":"124","categoryId2":"12416","ccListPic":{"notShowPic":1},"content_cid":"985128174855201090","highqualityKd":"1","imageShortContent":"","kbCategoryId1":"9","kbCategoryId2":"914","kdSrc":"52","kdSubSrc":"520002","levelSrcTag":"","rowkey":"1095f06d84380452","tags":"输液,科伦药业,药企,注射液,石四药集团,吸入剂","targetId":"5531476244"},"last_update_attr_time":"2020-07-09 18:40:09","link":"http://kuaibao.qq.com/s/20200709A0L1RH00","longtitle":"大输液龙头联盟坐拥140亿市场“求变”！科伦13个高端仿制来袭、石四药进军吸入剂","media_id":"6451326","mid":"2650375852","new_sn":"AAAAAFhQraTTenkdyGh0j-l8IuA","news_copyright":0,"news_update_time":1594284217,"om_url":"https://page.om.qq.com/page/OlewQooB7sXaoumqUH15srTA0","om_version_id":"20200709A0L1RH09","openid":"oCOnkjiCN8RiR9NEh1mYBiIiRoqQ","org_time":"2020-07-09 16:39:35","orig_media_id":null,"orig_src_id":"","origin_pool_flag":-1,"profession_info":{"name":"","organization":"","title":""},"pub_flag":"0","pub_time":"2020-07-09 16:39:35","publishDealTime":1594284665,"purchased":0,"qqnews_thu":"http://inews.gtimg.com/newsapp_ls/0/12060397152_150120/0","qqnews_thu_big":"http://inews.gtimg.com/newsapp_ls/0/12060397152_640330/0","refute_rumor_auth":0,"rel_weibo":{},"relate_modules":{"rel_news_ext":{"type":"auto"}},"remarks_name":"","rumor_text":{},"short_url":"","soso_category":null,"source":"1","spring_festival_flag":0,"src_type":2,"srcurl":"http://mp.weixin.qq.com/s?__biz=MjM5NzQ4MTg2MQ==\u0026mid=2650375852\u0026idx=1\u0026sn=cd9faa211d7e367f5a3b46f5569870fb\u0026chksm=bed47a4689a3f350","sub_source":"0","survey_id":"","tag":"","targetid":"5531466252","time":1594284665,"title":"大输液龙头联盟坐拥140亿市场“求变”！科伦13个高端仿制来袭、石四药进军吸入剂","title2":"","title_filterd":"大输液龙头联盟坐拥140亿市场“求变”！科伦13个高端仿制来袭、石四药进军吸入剂","type":"0","uin":"","url":"http://kuaibao.qq.com/s/20200709A0L1RH00","version":0,"video_category":"","voteId":"","wechat":"menetwx","_noAd":false},"id":"20200709A0L1RH00"},"type":"normal"}},"globalContext":{"pageKey":"article","qudao":"default","userAgent":"Wget/1.11.4","simpleUA":"others","skin":{"gray":false,"img":"https://mat1.gtimg.com/rain/bailing20/8b0ebf76e5ac.2020lianghui.png","bgcolor":"#F13C31","navcolor":"","navfontcolor":"","fontcolor":"","underlinecolor":"#FDEA40","biglogo":"","logo":"","starttime":"2020-05-19T00:00","endtime":"2020-05-29T12:00","hasSkin":false,"fromCache":true}}},"page":"/article/[id]","query":{"id":"20200709A0L1RH00"},"buildId":"bekAlVtaYh21RwYRjAoGs","assetPrefix":"https://mat1.gtimg.com/qqcdn/xw"}</script><script nomodule="" src="https://mat1.gtimg.com/qqcdn/xw/_next/static/runtime/polyfills-1170eb5e7956bbaa0d0e.js"></script><script async="" data-next-page="/article/[id]" src="https://mat1.gtimg.com/qqcdn/xw/_next/static/bekAlVtaYh21RwYRjAoGs/pages/article/%5Bid%5D.js"></script><script async="" data-next-page="/_app" src="https://mat1.gtimg.com/qqcdn/xw/_next/static/bekAlVtaYh21RwYRjAoGs/pages/_app.js"></script><script src="https://mat1.gtimg.com/qqcdn/xw/_next/static/runtime/webpack-18ae683764305191afa9.js" async=""></script><script src="https://mat1.gtimg.com/qqcdn/xw/_next/static/chunks/commons.0fb0bbc5a22735ff67b2.js" async=""></script><script src="https://mat1.gtimg.com/qqcdn/xw/_next/static/runtime/main-51bf4e043424b8340bb5.js" async=""></script></body></html>